Food, drug, insect sting allergy, and anaphylaxisRisk of anaphylaxis after vaccination in children and adults
Section snippets
Study population
Our study population included all children and adults enrolled in the health plans at 9 VSD sites who received 1 or more vaccines during the period from January 1, 2009 through December 31, 2011. Currently, the VSD has data on approximately 9.3 million subjects available annually, including 2.1 million children and 7.2 million adults.13 The participating VSD sites maintain automated databases of health care encounters, including immunization registries with detailed information on vaccines
Results
From January 1, 2009 through December 31, 2011, we identified a total of 17,606,500 vaccination visits at which a total 25,173,965 vaccine doses were administered. Among all visits, 1,117 potential anaphylaxis cases were identified by using electronic data. We identified 76 cases of chart-confirmed anaphylaxis (Brighton Levels 1 and 2); 33 anaphylaxis cases were associated with vaccination, and 43 were attributed to other causes.
Characteristics of the 33 cases of postvaccination anaphylaxis are
Discussion
In a large population-based study with extensive case finding, we identified 33 confirmed cases of anaphylaxis after administration of 25,173,965 vaccine doses or 1.31 (95% CI, 0.90-1.84) cases per million vaccine doses. With the largest number of doses and the largest number of cases, inactivated TIV was the major contributor to the number of vaccine-triggered anaphylaxis cases in the population, although the rate (1.35 [95% CI, 0.65-2.47] cases per million vaccine doses of TIV given alone)
References (48)
- et al.
Adverse reactions to vaccines
Ann Allergy Asthma Immunol
(2009) - et al.
Anaphylaxis after hepatitis B vaccination
Lancet
(1995) - et al.
Anaphylaxis: case definition and guidelines for data collection, analysis and presentation of immunization safety data
Vaccine
(2007) - et al.
The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety
Vaccine
(2014) - et al.
Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium
J Allergy Clin Immunol
(2006) - et al.
Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine
Vaccine
(2013) - et al.
Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective
Vaccine
(2011) - et al.
Adverse events following influenza A (H1N1) monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010
Vaccine
(2010) - et al.
Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring
Vaccine
(2009) - et al.
Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals
J Allergy Clin Immunol
(2014)
The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project
J Allergy Clin Immunol
Sexual dimorphism of humoral immunity with human vaccines
Vaccine
The Xs and Y of immune responses to viral vaccines
Lancet Infect Dis
Sex hormones as immunomodulators in health and disease
Int Immunopharmacol
Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric acid oxide synthetase expression and nitric oxide production
J Allergy Clin Immunol
Prescriptions for self-injectable epinephrine and follow-up referral in emergency department patients presenting with anaphylaxis
Ann Allergy Asthma Immunol
Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis
J Allergy Clin Immunol Pract
Longitudinal study of 954 patients with stinging insect anaphylaxis
Ann Allergy Asthma Immunol
Disease of immediate type hypersensitivity
Anaphylaxis
J Allergy Immunol
The diagnosis and management of anaphylaxis practice parameter: 2010 update
J Allergy Clin Immunol
World Allergy Organization guidelines for the assessment and management of anaphylaxis
J Allergy Clin Immunol
General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recomm Rep
Cited by (0)
The findings and conclusions of this report are those of the authors and do not necessarily represent the official policy or position of the Centers for Disease Control and Prevention (CDC). Use of trade names and commercial sources is for identification only and does not imply endorsement by the CDC. The Vaccine Safety Datalink Project is funded by the CDC. This study was supported by the CDC, and no external funding was secured.
Disclosure of potential conflict of interest: L. Sukumaran has received research support from the National Institutes of Health (NIH). N. P. Klein has received research and travel support, as well as payment for writing/reviewing the manuscript, from the Centers for Disease Control and Prevention (CDC) and has received research support from Sanofi Pasteur, GlaxoSmithKline, Novartis, MedImmune, Protein Science, Merck, Pfizer, and Nuron Biotech. S. J. Hambidge has received research support from the CDC Vaccine Safety Datalink. G. M. Lee and L. A. Jackson have received research support from the CDC. S. A. Irving has received research and travel support from the CDC. J. P. King has received research support from the CDC. The rest of the authors declare that they have no relevant conflicts of interest.